Page 8 - Subgroup Analysis News Today

AbbVie Showcases the Depth of its Rheumatology Portfolio with New Data Presented at the EULAR 2021 Virtual Congress of Rheumatology ABBVie today announced that it will present new data from a total of 41 abstracts covering its portfolio of immunology assets, including RINVOQ ® SKYRIZI ® HUMIRA ® and its pipeline across multiple rheumatic diseases at the EULAR 2021 Virtual Congress of Rheumatology, to be held virtually June 2-5 . Among the data presented will be new three-year and one-year ef...

NOVARTIS AG CHF0.50(REGD) Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177 Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be presented at ASCO ...

New Efficacy Data Reinforces NEXTSTELLIS® Benefits Across Patient Populations Results presented at the 2021 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting News provided by Share this article Share this article GREENVILLE, N.C., April 30, 2021 /PRNewswire/ -- Mayne Pharma announced today results from two studies showing treatment with NEXTSTELLIS® (3 mg drospirenone [DRSP] and 14.2 mg estetrol [E4] tablets) demonstrated contraceptive efficacy and exc...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Strongbridge Biopharma plc Announces Publication of Diabetes Subgroup Analysis from Phase 3 ... Strongbridge Biopharma plcApril 7, 2021 GMT RECORLEV® (levoketoconazole) Treatment Demonstrates Clinically Meaningful Improvements in Cortisol Control and Clinical Benefit in Patients with Cushing’s Syndrome and Comorbid Diabetes Mellitus DUBLIN, Ireland and TREVOSE, Pa., April 07, 2021 (GLOBE NEWSWIRE) ...